Tag: Glp 1 receptor agonist

In 2017, the manufacturer GlaxoSmithKline (GSK) announced the global withdrawal of Tanzeum (albiglutide) from the market. This means that while albiglutide is the generic name for the drug, there is no generic or branded version available today.

According to Drugs.com, Bydureon BCise is an extended-release formulation of exenatide that is injected once weekly for the treatment of Type 2 diabetes. This definitively answers the question, **Is Bydureon long acting or short acting?** by confirming its long-acting nature. Its long-acting profile is what differentiates it from its short-acting counterpart, Byetta, which contains the same active ingredient.

The International Diabetes Federation projects that by 2050, 1 in 8 adults will be living with diabetes. This has spurred the development of innovative drugs like semaglutide. So, **what is the pharmacological classification of semaglutide?**

Recent research from the SELECT trial showed that patients taking Wegovy for weight loss had a significantly reduced risk of death from COVID-19, sparking immense interest in its broader effects beyond metabolism. This discovery has led many to question: **Does Wegovy impact your immune system?** Emerging evidence suggests the drug primarily modulates immune activity with beneficial anti-inflammatory effects.

While most people are familiar with the injectable versions, Rybelsus is the oral tablet version of semaglutide. This provides a needle-free alternative for adults with type 2 diabetes and expands the options available for managing blood sugar levels. The development of this medication addresses patient preferences while utilizing the same active ingredient to achieve similar therapeutic goals.

Based on recent clinical trial findings, Efpeglenatide, an investigational glucagon-like peptide-1 receptor agonist (GLP-1 RA), has demonstrated significant improvements in glycemic control and body weight loss for patients with type 2 diabetes (T2D). The drug’s potential indications extend beyond blood sugar management, showing promising results for reducing cardiovascular and renal risks in high-risk patient populations.

Roughly 12% of U.S. adults have tried GLP-1 medications, a class of drugs that first entered the market in 2005 [1.3.5]. So, what is a GLP-1 drug? These are synthetic hormones that mimic the body's natural glucagon-like peptide-1, primarily used to manage type 2 diabetes and obesity [1.2.2, 1.3.4].

In 2024, an estimated 26.5% of adults with diagnosed diabetes in the U.S. used a GLP-1 injectable like Ozempic [1.8.3]. With its rising popularity, many people ask: **Is Ozempic insulin?** The answer is no; they are entirely different medications with distinct mechanisms for managing blood sugar [1.5.3, 1.5.4].